Health · Medical Research · 2 hrs ago
Review finds possible reproductive benefits of GLP-1 drugs for women with PCOS
Researchers reviewed 28 studies of GLP-1 drugs in women with PCOS to examine reproductive and gynecologic effects beyond weight loss.
PCOS is a common hormone and metabolic condition that can involve insulin resistance and irregular menstrual cycles.
Some studies found more regular periods after treatment, especially among people who lost significant weight, but other studies found no clear change.
Some evidence pointed to improved ovulation, particularly when GLP-1 drugs were used with metformin.
One small trial found higher pregnancy rates during later IVF after liraglutide plus metformin than after metformin alone.
The findings were mixed, as the studies used different treatments and measures, so the review does not establish how well these drugs work for reproductive outcomes.
Pregnancy safety was not assessed, and separate clinical guidance recommends stopping GLP-1 drugs before trying to conceive because safety data are limited.
A scoping review found possible improvements in menstrual function, ovulation and fertility outcomes among women with PCOS treated with GLP-1 drugs.
The review included 28 studies, with liraglutide, exenatide and semaglutide among the treatments assessed.
Three studies reported improved menstrual frequency or regularity, while other studies found no significant difference in menstrual outcomes.
A small pilot trial involving 28 women reported higher pregnancy rates after IVF among those given liraglutide plus metformin before conception than among those given metformin alone.
The review did not assess pregnancy safety, and the article says separate clinical guidance recommends stopping GLP-1 drugs before planned conception because safety data are limited.
- Who
- Researchers at Nova Southeastern University reviewed evidence on GLP-1 drugs in women with PCOS.
- What
- The review found possible reproductive and gynecologic benefits, including improvements in menstrual function and ovulation.
- When
- The review was published on 2026-11-02.
- Where
- The research was conducted at Nova Southeastern University in Davie, USA.
- Why
- The researchers examined evidence on gynecologic and reproductive outcomes associated with GLP-1 treatment in women with PCOS.
This story does not have two clearly opposing sides.
Researchers searched four databases for studies of GLP-1 treatment and reproductive or gynecologic outcomes in women with PCOS.
After deduplication, researchers screened 697 records and reviewed 76 articles in full.
The researchers included 28 studies in the scoping review.
News-Medical published its report on the review.
- Studies included
- 28
- Records identified
- 1,416
- Unique records screened
- 697
- Full-text articles reviewed
- 76
- Most assessed drug
- Liraglutide, evaluated in 15 studies
- Pilot trial
- 28 women; liraglutide plus metformin before IVF was associated with higher pregnancy rates than metformin alone